Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Clinical trial NCT04935359 · COMPLETED
Trial details
- NCT number
- NCT04935359
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-30
- Primary completion
- 2024-08-13
- Enrollment
- 511
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.